Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Open-label Clinical Trial Demonstrating the Safety of RBX2660 Microbiota Suspension for the Treatment of Recurrent Clostridium Difficile-associated Diarrhea (CDAD): the PUNCH CD Study

NCT01925417 is registered in ClinicalTrials.gov with Rebiotix Inc. as lead sponsor.

NCT NCT01925417
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01925417 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Open-label Clinical Trial Demonstrating the Safety of RBX2660 Microbiota Suspension for the Treatment of Recurrent Clostridium Difficile-associated Diarrhea (CDAD): the PUNCH CD Study
Lead sponsor
Rebiotix Inc.
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2013
Completion date
July 31, 2014
Enrollment
34 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent clostridium difficile infection